Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Yixintang Pharmaceutical Group

SZSE:002727
Snowflake Description

Excellent balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
002727
SZSE
CN¥14B
Market Cap
  1. Home
  2. CN
  3. Consumer Retailing
Company description

Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, operates a chain of drugstores in China. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Yixintang Pharmaceutical Group has significant price volatility in the past 3 months.
002727 Share Price and Events
7 Day Returns
-0.1%
SZSE:002727
2.5%
CN Consumer Retailing
-0.1%
CN Market
1 Year Returns
0.4%
SZSE:002727
14.8%
CN Consumer Retailing
-9.2%
CN Market
002727 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Yixintang Pharmaceutical Group (002727) -0.1% 12.7% 5.5% 0.4% 20.5% -35.2%
CN Consumer Retailing 2.5% 3.9% 16.9% 14.8% 11.1% -6.5%
CN Market -0.1% -9.8% -6.1% -9.2% -16.2% -26.5%
1 Year Return vs Industry and Market
  • 002727 underperformed the Consumer Retailing industry which returned 14.8% over the past year.
  • 002727 outperformed the Market in China which returned -9.2% over the past year.
Price Volatility
002727
Industry
5yr Volatility vs Market

Value

 Is Yixintang Pharmaceutical Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Yixintang Pharmaceutical Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Yixintang Pharmaceutical Group.

SZSE:002727 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year CN Government Bond Rate 3.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SZSE:002727
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CN Govt Bond Rate 3.2%
Equity Risk Premium S&P Global 6.3%
Consumer Retailing Unlevered Beta Simply Wall St/ S&P Global 0.48
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.483 (1 + (1- 25%) (3.35%))
0.662
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.2% + (0.8 * 6.33%)
8.26%

Discounted Cash Flow Calculation for SZSE:002727 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Yixintang Pharmaceutical Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SZSE:002727 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 8.26%)
2020 368.00 Analyst x1 339.91
2021 618.00 Analyst x1 527.25
2022 626.33 Est @ 1.35% 493.57
2023 638.24 Est @ 1.9% 464.57
2024 652.87 Est @ 2.29% 438.94
2025 669.62 Est @ 2.56% 415.84
2026 688.06 Est @ 2.76% 394.68
2027 707.94 Est @ 2.89% 375.08
2028 729.05 Est @ 2.98% 356.78
2029 751.27 Est @ 3.05% 339.59
Present value of next 10 years cash flows CN¥4,146.00
SZSE:002727 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥751.27 × (1 + 3.2%) ÷ (8.26% – 3.2%)
CN¥15,310.20
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥15,310.20 ÷ (1 + 8.26%)10
CN¥6,920.54
SZSE:002727 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥4,146.00 + CN¥6,920.54
CN¥11,066.54
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥11,066.54 / 567.77
CN¥19.49
SZSE:002727 Discount to Share Price
Calculation Result
Value per share (CNY) From above. CN¥19.49
Current discount Discount to share price of CN¥25.36
= -1 x (CN¥25.36 - CN¥19.49) / CN¥19.49
-30.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Yixintang Pharmaceutical Group is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Yixintang Pharmaceutical Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Yixintang Pharmaceutical Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SZSE:002727 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CNY CN¥1.06
SZSE:002727 Share Price ** SZSE (2020-04-03) in CNY CN¥25.36
China Consumer Retailing Industry PE Ratio Median Figure of 20 Publicly-Listed Consumer Retailing Companies 42.97x
China Market PE Ratio Median Figure of 3,196 Publicly-Listed Companies 32.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Yixintang Pharmaceutical Group.

SZSE:002727 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SZSE:002727 Share Price ÷ EPS (both in CNY)

= 25.36 ÷ 1.06

23.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Yixintang Pharmaceutical Group is good value based on earnings compared to the CN Consumer Retailing industry average.
  • Yixintang Pharmaceutical Group is good value based on earnings compared to the China market.
Price based on expected Growth
Does Yixintang Pharmaceutical Group's expected growth come at a high price?
Raw Data
SZSE:002727 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 23.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
16.4%per year
China Consumer Retailing Industry PEG Ratio Median Figure of 14 Publicly-Listed Consumer Retailing Companies 2.19x
China Market PEG Ratio Median Figure of 1,275 Publicly-Listed Companies 1.26x

*Line of best fit is calculated by linear regression .

SZSE:002727 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 23.84x ÷ 16.4%

1.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Yixintang Pharmaceutical Group is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Yixintang Pharmaceutical Group's assets?
Raw Data
SZSE:002727 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CNY CN¥8.09
SZSE:002727 Share Price * SZSE (2020-04-03) in CNY CN¥25.36
China Consumer Retailing Industry PB Ratio Median Figure of 21 Publicly-Listed Consumer Retailing Companies 2.71x
China Market PB Ratio Median Figure of 3,691 Publicly-Listed Companies 2.26x
SZSE:002727 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SZSE:002727 Share Price ÷ Book Value per Share (both in CNY)

= 25.36 ÷ 8.09

3.13x

* Primary Listing of Yixintang Pharmaceutical Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Yixintang Pharmaceutical Group is overvalued based on assets compared to the CN Consumer Retailing industry average.
X
Value checks
We assess Yixintang Pharmaceutical Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Consumer Retailing industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Consumer Retailing industry average (and greater than 0)? (1 check)
  5. Yixintang Pharmaceutical Group has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Yixintang Pharmaceutical Group expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Yixintang Pharmaceutical Group expected to grow at an attractive rate?
  • Yixintang Pharmaceutical Group's earnings growth is expected to exceed the low risk savings rate of 3.2%.
Growth vs Market Checks
  • Yixintang Pharmaceutical Group's earnings growth is positive but not above the China market average.
  • Yixintang Pharmaceutical Group's revenue growth is expected to exceed the China market average.
Annual Growth Rates Comparison
Raw Data
SZSE:002727 Future Growth Rates Data Sources
Data Point Source Value (per year)
SZSE:002727 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 16.4%
SZSE:002727 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 16.2%
China Consumer Retailing Industry Earnings Growth Rate Market Cap Weighted Average 22.2%
China Consumer Retailing Industry Revenue Growth Rate Market Cap Weighted Average 17.3%
China Market Earnings Growth Rate Market Cap Weighted Average 20.9%
China Market Revenue Growth Rate Market Cap Weighted Average 15.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SZSE:002727 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SZSE:002727 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 17,053 718 1,017 3
2021-12-31 14,719 1,034 840 8
2020-12-31 12,293 680 724 3
2020-04-04
SZSE:002727 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-12-31 10,479 983 604
2019-09-30 10,219 1,017 587
2019-06-30 9,945 892 566
2019-03-31 9,585 988 565
2019-01-01 9,176 636 521
2018-09-30 8,768 619 525
2018-06-30 8,391 579 499
2018-03-31 8,116 330 457
2017-12-31 7,751 391 423
2017-09-30 7,316 166 386
2017-06-30 6,949 44 373
2017-03-31 6,584 134 345

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Yixintang Pharmaceutical Group's earnings are expected to grow by 16.4% yearly, however this is not considered high growth (20% yearly).
  • Yixintang Pharmaceutical Group's revenue is expected to grow by 16.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SZSE:002727 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Yixintang Pharmaceutical Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SZSE:002727 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 1.79 1.87 1.71 3.00
2021-12-31 1.48 1.67 1.19 9.00
2020-12-31 1.28 1.29 1.25 5.00
2020-04-04
SZSE:002727 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-12-31 1.06
2019-09-30 1.03
2019-06-30 1.00
2019-03-31 1.00
2019-01-01 0.92
2018-09-30 0.94
2018-06-30 0.92
2018-03-31 0.86
2017-12-31 0.81
2017-09-30 0.74
2017-06-30 0.72
2017-03-31 0.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Yixintang Pharmaceutical Group is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Yixintang Pharmaceutical Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Yixintang Pharmaceutical Group has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Yixintang Pharmaceutical Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Yixintang Pharmaceutical Group's growth in the last year to its industry (Consumer Retailing).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Yixintang Pharmaceutical Group's year on year earnings growth rate has been positive over the past 5 years.
  • Yixintang Pharmaceutical Group's 1-year earnings growth exceeds its 5-year average (15.9% vs 14.8%)
  • Yixintang Pharmaceutical Group's earnings growth has not exceeded the CN Consumer Retailing industry average in the past year (15.9% vs 24%).
Earnings and Revenue History
Yixintang Pharmaceutical Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Yixintang Pharmaceutical Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SZSE:002727 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 10,479.09 603.92 3,245.49 0.24
2019-09-30 10,218.52 586.62 3,150.15 0.38
2019-06-30 9,944.59 565.85 3,026.13 0.38
2019-03-31 9,585.27 565.07 2,922.91 0.32
2019-01-01 9,176.27 521.07 2,845.17 0.15
2018-09-30 8,767.87 525.28 2,740.17
2018-06-30 8,391.39 499.02 2,679.08
2018-03-31 8,116.09 456.76 2,611.89
2017-12-31 7,751.14 422.71 2,496.96
2017-09-30 7,316.33 385.61 2,336.14
2017-06-30 6,949.03 373.29 2,229.30
2017-03-31 6,584.39 344.93 2,091.91
2016-12-31 6,249.34 353.38 2,035.51
2016-09-30 5,970.60 378.63 1,996.84
2016-06-30 5,773.83 368.51 1,925.42
2016-03-31 5,599.92 361.39 1,886.97
2015-12-31 5,321.15 346.26 1,747.09
2015-09-30 5,080.48 323.30 1,597.04
2015-06-30 4,853.63 313.74 1,472.01
2015-03-31 4,589.31 309.80 1,390.04
2014-12-31 4,428.41 297.31 1,331.96
2014-09-30 4,235.79 291.65 1,296.81
2014-06-30 3,995.29 278.52 1,232.69
2014-03-31 3,791.77 252.90 1,392.42
2013-12-31 3,546.66 240.85 1,080.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Yixintang Pharmaceutical Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Yixintang Pharmaceutical Group used its assets more efficiently than the CN Consumer Retailing industry average last year based on Return on Assets.
  • Yixintang Pharmaceutical Group has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Yixintang Pharmaceutical Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Consumer Retailing industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Yixintang Pharmaceutical Group has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Yixintang Pharmaceutical Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Yixintang Pharmaceutical Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Yixintang Pharmaceutical Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Yixintang Pharmaceutical Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Yixintang Pharmaceutical Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 11.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Yixintang Pharmaceutical Group Company Filings, last reported 3 months ago.

SZSE:002727 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 4,596.17 482.82 2,401.03
2019-09-30 4,467.55 889.74 1,310.42
2019-06-30 4,320.33 883.70 2,227.72
2019-03-31 4,055.43 399.29 1,395.36
2019-01-01 4,054.95 814.93 1,978.15
2018-09-30 3,947.84 798.30 1,279.46
2018-06-30 3,819.72 1,197.38 1,899.86
2018-03-31 3,828.38 1,196.40 1,008.15
2017-12-31 3,693.94 1,295.43 2,195.98
2017-09-30 2,709.58 1,294.30 1,120.52
2017-06-30 2,609.94 1,195.81 1,034.80
2017-03-31 2,595.30 1,195.23 1,110.88
2016-12-31 2,498.13 1,594.28 1,910.54
2016-09-30 2,428.58 797.73 1,139.15
2016-06-30 2,340.56 802.18 1,121.30
2016-03-31 2,378.74 800.00 1,148.78
2015-12-31 2,279.55 625.00 1,082.02
2015-09-30 2,177.91 428.00 1,027.40
2015-06-30 2,100.52 333.00 1,102.51
2015-03-31 2,017.13 150.00 1,044.50
2014-12-31 2,082.72 0.00 1,056.28
2014-09-30 2,022.84 0.00 972.30
2014-06-30 1,955.57 220.00 1,270.85
2014-03-31 1,127.57 0.00 532.95
2013-12-31 1,050.13 220.00 520.43
  • Yixintang Pharmaceutical Group's level of debt (10.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.1% vs 10.5% today).
  • Debt is well covered by operating cash flow (203.6%, greater than 20% of total debt).
  • Yixintang Pharmaceutical Group earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Yixintang Pharmaceutical Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Yixintang Pharmaceutical Group has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Yixintang Pharmaceutical Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.18%
Current annual income from Yixintang Pharmaceutical Group dividends. Estimated to be 1.95% next year.
If you bought CN¥2,000 of Yixintang Pharmaceutical Group shares you are expected to receive CN¥24 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Yixintang Pharmaceutical Group's pays a higher dividend yield than the bottom 25% of dividend payers in China (0.46%).
  • Yixintang Pharmaceutical Group's dividend is below the markets top 25% of dividend payers in China (2.04%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SZSE:002727 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
China Consumer Retailing Industry Average Dividend Yield Market Cap Weighted Average of 17 Stocks 0.9%
China Market Average Dividend Yield Market Cap Weighted Average of 2585 Stocks 1.9%
China Minimum Threshold Dividend Yield 10th Percentile 0.2%
China Bottom 25% Dividend Yield 25th Percentile 0.5%
China Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SZSE:002727 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.56 1.00
2021-12-31 0.52 4.00
2020-12-31 0.45 4.00
2020-04-04
SZSE:002727 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2020-03-20 0.300 1.238
2019-03-22 0.300 1.217
2018-05-30 0.300 1.240
2017-04-06 0.200 0.966
2016-03-23 0.250 1.126
2015-03-11 0.300 1.207

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Yixintang Pharmaceutical Group has been paying a dividend for less than 10 years.
  • Yixintang Pharmaceutical Group has only been paying a dividend for 5 years, and since then there has been no growth.
Current Payout to shareholders
What portion of Yixintang Pharmaceutical Group's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.5x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.2x coverage).
X
Income/ dividend checks
We assess Yixintang Pharmaceutical Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Yixintang Pharmaceutical Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Yixintang Pharmaceutical Group has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Yixintang Pharmaceutical Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hong Xian Ruan
COMPENSATION CN¥242,000
AGE 53
TENURE AS CEO 6.3 years
CEO Bio

Mr. Hong Xian Ruan has been President and Non-Independent Director at Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. since December 02, 2013 and November 18, 2013.

CEO Compensation
  • Insufficient data for Hong Xian to compare compensation growth.
  • Hong Xian's remuneration is lower than average for companies of similar size in China.
Management Team Tenure

Average tenure and age of the Yixintang Pharmaceutical Group management team in years:

6.3
Average Tenure
33
Average Age
  • The average tenure for the Yixintang Pharmaceutical Group management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Hong Xian Ruan

TITLE
President and Non-Independent Director
COMPENSATION
CN¥242K
AGE
53
TENURE
6.3 yrs

Jun Tian

TITLE
CFO, VP & Secretary of the Board
COMPENSATION
CN¥181K
TENURE
6.3 yrs

Hongyun Zhou

TITLE
Vice President
COMPENSATION
CN¥181K
TENURE
6.3 yrs

Yongjun Wu

TITLE
Vice President
COMPENSATION
CN¥180K
TENURE
6.3 yrs

Yongbin Luo

TITLE
Vice President and Senior Executive
COMPENSATION
CN¥181K
TENURE
5.3 yrs

Zheng Hong Li

TITLE
Deputy Director of Accounting and Member of Supervisory Board
AGE
33
TENURE
5.7 yrs

Guan Yin

TITLE
Dy Mngr-Securities Dept
AGE
32
TENURE
6.3 yrs
Board of Directors Tenure

Average tenure and age of the Yixintang Pharmaceutical Group board of directors in years:

4.1
Average Tenure
33
Average Age
  • The tenure for the Yixintang Pharmaceutical Group board of directors is about average.
Board of Directors

Hong Xian Ruan

TITLE
President and Non-Independent Director
COMPENSATION
CN¥242K
AGE
53
TENURE
6.4 yrs

Zheng Hong Li

TITLE
Deputy Director of Accounting and Member of Supervisory Board
AGE
33
TENURE
5.6 yrs

Guan Yin

TITLE
Dy Mngr-Securities Dept
AGE
32
TENURE
4.8 yrs

Feng Guang Lu

TITLE
Chairman of Board of Supervisors
TENURE
6.4 yrs

Qiong Liu

TITLE
Non-Independent Director
TENURE
6.4 yrs

Guo Chunli

TITLE
Non-Independent Director
TENURE
3.4 yrs

Long Xiaohai

TITLE
Independent Director
TENURE
0.4 yrs

Zhang Yong

TITLE
Non-Independent Director
TENURE
0.4 yrs

Chen Xudong

TITLE
Independent Director
TENURE
0.4 yrs

Ruan Guowei

TITLE
Non-Independent Director
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CN¥) Value (CN¥)
X
Management checks
We assess Yixintang Pharmaceutical Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Yixintang Pharmaceutical Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, operates a chain of drugstores in China. It processes and sells medicinal materials; and engages in the wholesale of Chinese and western medicines. As of January 31, 2019, owned 5,872 direct chain stores in Yunnan, Guizhou, Guangxi, Sichuan, Shanxi, Chongqing, Tianjin, Shanghai, Hainan, and Henan provinces. It also sells products online. The company was formerly known as Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. and changed its name to Yixintang Pharmaceutical Group Co., Ltd. in June 2019. Yixintang Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Kunming, China.

Details
Name: Yixintang Pharmaceutical Group Co., Ltd.
002727
Exchange: SZSE
Founded: 2000
CN¥14,398,700,329
567,772,095
Website: http://www.hx8886.com
Address: Yixintang Pharmaceutical Group Co., Ltd.
No.1, Hongxiang Road,
Economic Development Zone,
Kunming,
Yunnan Province, China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SZSE 002727 Domestic shares Shenzhen Stock Exchange CN CNY 02. Jul 2014
XSEC 002727 Domestic shares Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect CN CNY 02. Jul 2014
Number of employees
Current staff
Staff numbers
26,999
Yixintang Pharmaceutical Group employees.
Industry
Drug Retail
Consumer Retailing
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 18:51
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/19
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.